A joint research team of the Korea Advanced Institute of Science and Technology (KAIST) and domestic biotechnology firm Neogenlogic has developed a new artificial intelligence (AI) model that can help produce a whole new type of "personalised" cancer vaccine, the joint team said on Friday. 

The new AI platform helps identify neoantigens unique to each cancer patient that can train the patient`s immune system, and thus prevent recurrence of the illness, reports Yonhap news agency.